10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 3,500,000 | $13,510,000 | -13% | 0.24% |
| 2. | Millennium Management Israel Englander | 3,428,571 | $13,234,284 | +83% | 0.01% |
| 3. | Vestal Point Capital Ryan Wilder | 3,002,936 | $11,591,333 | +104% | 0.32% |
| 4. | Opaleye Management James A. Silverman | 1,150,000 | $4,439,000 | -4% | 0.58% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 615,660 | $2,376,448 | +884% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.88 | 4,395,588 | $39,032,821.44 | 8,575,316 | 2023-02-23 | Filing | |
| $5.66 | 376,000 | $2,126,543.20 | 4,753,907 | 2022-06-23 | Filing | |
| $5.28 | 101,400 | $535,503.54 | 4,377,907 | 2022-06-21 | Filing | |
| $11.96 | 4,179,728 | $49,999,996.20 | 4,179,728 | 2019-03-12 | Filing | |
| $19.39 | 3,000 | $58,170.00 | 76,588 | 2018-09-10 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.87 | 11,511 | $44,547.57 | 472,549 | 2026-04-02 | Filing | |
| $3.77 | 6,458 | $24,346.66 | 199,738 | 2026-02-24 | Filing | |
| $3.79 | 14,197 | $53,806.63 | 484,060 | 2026-02-24 | Filing | |
| $3.77 | 4,668 | $17,598.36 | 151,416 | 2026-02-24 | Filing | |
| $3.76 | 4,174 | $15,694.24 | 145,718 | 2026-02-24 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,568,381 | $21,493,950 | 0% | |
| 2. | 2,283,253 | $8,813,357 | 0% | |
| 3. | 1,095,141 | $4,238,196 | 0.04% | |
| 4. | 1,049,978 | $4,054,437 | 0% | |
| 5. | 948,226 | $3,660,152 | 0% |